Purpose: Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades.
introduction
Lung cancer is the leading cause of cancer deaths in many countries [1] , with non-small-cell lung cancer (NSCLC) accounting for 75% of lung cancer cases. The majority of NSCLC patients have inoperable, locally advanced, or metastatic disease at the time of diagnosis. Cisplatin-based chemotherapy offers survival benefit and symptom relief for this subpopulation [2] [3] [4] , and a large number of NSCLC patients currently receive chemotherapy worldwide. In addition to cisplatin, several new chemotherapeutic agents have been developed and introduced into clinical trials [5] . The treatment outcome of NSCLC patients enrolled in phase III systemic chemotherapy trials has improved modestly, but significantly, over the past two decades [6] .
Unfortunately, the goal of systemic chemotherapy in patients with advanced NSCLC is often still symptomatic relief, rather than significant prolongation of survival, as the survival benefit of chemotherapy is limited. Chemotherapy-related toxicity sometimes leads to treatment-related deaths and often to a deterioration in the patient's quality of life. Thus, toxicity profile information and data on the efficacy of phase III trials are essential for a full discussion by physicians and patients in clinical practice [7] .
Sepsis with severe neutropenia is the most common causes of fatal toxicity during the administration of chemotherapy agents [8] , and historically, a small percentage of patients have died during these treatments. However, changes in the incidence of such deaths over the years have not been fully evaluated. Given that the estimated number of patients newly diagnosed with lung cancer worldwide is >1 300 000 per year [1] , treatment-related deaths (TRDs) totaling 0.1% would result in thousands of patient deaths each year due to treatment toxicity. Additionally, the clinical introduction of new agents may have changed the pattern of TRDs, but this has not been systematically assessed.
Thus, we investigated time trends in the incidence and pattern of TRDs, as well as their relationship to different chemotherapy regimens, using a database of phase III systemic treatment trials.
patients and methods

search for trials
We conducted a search for trials reported from January 1991 to August 2008. To avoid publication bias, both published and unpublished trials were identified through a computer search of the PubMed database and abstracts from the past 10 conferences of the American Society of Clinical Oncology, using the following search terms: 'lung neoplasm', 'carcinoma', 'non-small cell', 'chemotherapy', and 'randomised controlled trial'. The search was also guided by a thorough examination of reference lists in original articles, review articles, and relevant books, as well as the Physician Data Query registry of clinical trials.
selection of trials
Phase III trials that compared systemic treatment of advanced or metastatic NSCLC with cytotoxic agents or molecular-targeted agents were eligible. Trials that investigated only immunotherapy regimens were excluded. Trials initially designed to assess combined modality treatments, including radiotherapy and surgery, were also excluded.
data abstraction
To avoid bias in the data abstraction process, two observers (YF and KH), one of whom (KH) is board certified in medical oncology, independently abstracted trial data and subsequently compared results. The following information was obtained from each report: year of publication, publication type, toxicity criteria, chemotherapy regimen, and number of TRDs (per treatment arm). Docetaxel (Taxotere; Aventis Pharmaceuticals, Bridgewater, NJ), paclitaxel (Taxol; Bristol-Myers Squibb Co., Wallingford, CT), vinorelbine, gemcitabine, and irinotecan were defined as newer chemotherapeutic agents [9] . Drugs believed to act on known specific molecular targets, such as tyrosine kinase inhibitors, neutralizing antibodies, matrix metalloproteinase inhibitors, and antisense oligonucleotides were defined as molecular-targeted agents [10] . All data were checked for internal consistency, and disagreements were resolved by discussion among the investigators.
definition of TRD
'Treatment-related' death was basically defined by the relevant description in each article: all deaths reported by investigators as 'possibly', 'probably', or 'definitely' related to treatment were considered toxicity-related deaths, as reported previously [11] . To verify that adverse events were treatment related, we tried to contact the principal investigators of the trials to confirm or update the published data. The data we collected from each trial included not only the overall number of TRDs but also the number stratified by representative cause (toxicity profile) as follows: febrile neutropenia, hemorrhage, renal failure, central nervous system (CNS) disorder, cardiovascular disease, pulmonary disorder, and interstitial lung disease (ILD). Hemoptysis, upper and lower gastrointestinal hemorrhages, and disseminated intravascular coagulation-related hemorrhage were all categorized as 'hemorrhage', while both CNS ischemia and hemorrhage were classified as 'CNS disorder'. 'Cardiovascular disease' included ischemia, infarction, or embolism in any organ other than the CNS (i.e. myocardial infarction and pulmonary embolism). 'Pulmonary disorders' included all pulmonary diseases other than pulmonary embolisms, including infection without neutropenia (i.e. pneumonia) and ILD. 'ILD' has recently become an important clinical and social issue, especially in Japan [12] , and thus, this toxicity profile was also separately assessed here. We applied the definition of ILDs that was used in each eligible trial and then extracted their actual numbers, although we basically recognized the ILDs as follows: a clinical syndrome characterized by the onset of a dry cough and hypoxemia, accompanied by interstitial pulmonary infiltrates on a chest radiograph or computed tomography scan or both [13] [14] [15] .
quantitative data synthesis 
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incidence during the observation period, we calculated this number for each year of publication. The association between the year of publication and incidence of TRDs was analyzed using linear regression analysis, weighted by sample size. The significance of differences among three and two independent groups was determined by the Kruskal-Wallis and MannWhitney U tests, respectively. All P values corresponded to two-sided tests, and significance was set at P < 0.05. Statistical analyses were conducted using the STATA software (version 10; StataCorp, College Station, TX). Figure 1 shows a time chart of this study. In total, we identified 119 trials involving 49 162 patients with advanced NSCLC by computer and manual searches of relevant articles, abstracts, and references. Among these, 46 477 patients were allocated randomly to 263 chemotherapy arms. Table 1 lists the baseline characteristics of the trials. Most studies were published as full text (88%), with toxicity criteria described in 78% of the trials. Approximately half of the trials used the toxicity criteria of the World Health Organization.
trends in chemotherapy arm types
The 119 phase III trials included 263 chemotherapeutic treatment arms (Table 2 ). Figure 2 illustrates trends in the chemotherapy arm types. We divided the trials into three generations, based on the year of publication, in three 6-year periods (1991-1996, 1997-2002, and 2003-2008) . As expected, the proportion of cisplatin and older agent regimens decreased during the study period, whereas combinations of cisplatin with newer agents, carboplatin-based regimens, new nonplatinum agent regimens, and molecular-targeted therapies increased.
TRD incidence and time trends
Data for the calculation of the overall incidence of TRDs were available from all 119 trials with their 263 chemotherapy arms (46 477 patients), whereas information about causes of deaths was provided for 197 arms (75%, 30 147 patients). The crude TRD rate of the overall cohort was 1.26%. When this rate was stratified by cause of death, the most common cause was febrile neutropenia (0.50%), followed by cardiovascular diseases (0.25%; Table 2 ). Next, we assessed time trends in the TRD rate ( Figure 3 ). The overall TRD rate was stable over the observed period, with a regression coefficient of 20.010 (P = 0.762), corresponding to a TRD decrease of 0.01% per year ( Figure 3A) . Additionally, the time trend of the TRD rate in terms of cause of death showed that deaths due to renal toxicity decreased significantly (P = 0.042; Figure 3D ), whereas those due to pulmonary disorders increased significantly (P = 0.007; Figure 3G ). Among pulmonary disorders, TRD due to ILD similarly increased (P = 0.011; Figure 3H ). Other profiles, including febrile neutropenia, showed no significant trend over time.
To clarify the clinical backgrounds potentially associated with these time trends, we calculated the TRD rate stratified by type of chemotherapy. Notably, chemotherapy regimens in the second-line setting were significantly associated with pulmonary disorder (P < 0.001; Figure 4A ), whereas deaths from febrile neutropenia were observed more frequently as the number of agents combined increased (P = 0.060; Figure 4B ). TRDs due to febrile neutropenia were similarly observed across all regimens, except that several single-agent therapies and nonplatinum regimens induced no deaths from renal failure (Table 2) . Additionally, both docetaxel, a new cytotoxic agent, and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resulted more often in deaths from pulmonary disorders than did older agents (P < 0.001 and P = 0.001; Figure 4C and D) . Notably, EGFR-TKIs induced no other type of TRD, whereas hemorrhage and cardiovascular diseases were dominant causes of death in treatments with antibodies against vascular endothelial growth factor (0.88% and 1.24%, respectively; Table 2 ).
discussion
In 119 phase III trials involving 46 477 patients, we found that (i) the overall TRD rate was 1.26% and was largely stable over the past 19 years; (ii) the most common cause of TRD was febrile neutropenia, with no significant change in incidence over the study period; (iii) deaths due to renal toxicity decreased significantly ( Figure 3D ), whereas those due to pulmonary disorder increased significantly ( Figure 3G) ; and (iv) among the chemotherapeutic agents investigated, docetaxel and EGFR-TKIs resulted in relatively high death rates from pulmonary disorders ( Figure 4C and D) , although EGFR-TKIs were not associated with deaths from any other cause (Table 2) .
Similarly, the TRD rate remained relatively constant from 1991 to 2002 in phase I trial settings [11] . Notably, our investigation revealed that time trends in TRD varied by TRD cause. Most problematic for clinicians seems our finding that febrile neutropenia, the major cause of TRD, has not significantly decreased over the past two decades, despite the development of supportive care, including granulocyte colonystimulating factors. Moreover, deaths from pulmonary disorders, especially ILD, have increased over the years. Among regimens, docetaxel and EGFR-TKIs appear to induce predominantly pulmonary disorders (Table 2) , as reported previously [12, 16] . These agents have primarily been introduced into phase III trials in a late period as second-line setting (Figure 2 ). This most likely explains the increase in pulmonary disorders in the whole group of trials analyzed and, in particular, in the second-line setting.
In contrast, deaths from renal failure have decreased. This may be attributable to patient selection and improved supportive care over the years. Additionally, various regimens other than cisplatin-based regimens that induce less renal toxicity have been investigated (Figure 2) . Carboplatin-based regimens especially have been frequently investigated in phase III trials because of the lack of severe nephrotoxicity and good treatment compliance in an outpatient setting [3, 4] . All of these potential factors may have contributed to the decrease in deaths from renal failure. 
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In phase I oncology trials, TRD rates vary widely, as early clinical trials investigate various types of compounds, including immunomodulators, gene transfers, and vaccines, in addition to conventional cytotoxic agents [11] . Thus, our study of phase III trial data revealed less intertrial arm variability in the TRD rate ( Table 2 ). The phase III trials assessed here evaluated few agents other than cytotoxic drugs as alternative investigations have usually been terminated in early clinical trials due to lack of antitumor activity. However, as molecular-targeted agents with unique mechanisms of action are more extensively developed [17] , both the incidence and pattern of TRD will vary more complexly in the future.
Although we focused primarily on the safety of various anticancer agents, the benefits are obviously as important as the risks when assessing the utility of investigational agents for cancer patients. We demonstrated several possible relationships between renal toxicity and cisplatin, but not carboplatin, between pulmonary disorders and docetaxel and EGFR-TKIs, and between hemorrhage and cardiovascular diseases and antibodies against vascular endothelial growth factors. However, cisplatin is superior to carboplatin in terms of overall survival [3, 4] , docetaxel has survival advantages over vinorelbine, another new cytotoxic agent, and older agents combined with cisplatin [18] and gefitinib, one of the EGFRTKIs, yield a longer progression-free survival time than do carboplatin and paclitaxel [19] . Thus, our intention is not to suggest that agents with severe toxicity profiles are no longer useful, but simply to report safety profiles and long-term trends in TRDs.
Our study has several limitations. First, this analysis tried to cast a wide net to capture many heterogeneous studies for the database, and the results in this study potentially have several confounders and uncertainty. The results are generally uninterpretable without the appropriate adjustment for relevant patient, tumor, and treatment characteristics. Actually, our analyses were not based on individual patient data: differences in patient characteristics, unlike differences in trial arm characteristics, directly affect toxicity profiles. For example, ILD events frequently occur in patients with a smoking history and poor performance in EGFR-TKI treatment [12] . Second, we did not have a priori statistical plan since we studied retrospectively. Third, a potential publication bias may also exist. Severe toxic agents or regimens may not have been reported, resulting in an underestimation of the TRD rate. In addition, TRD secondary to platinum-based chemotherapy can be viewed in relation with time, while the TRD following prescription of EGFR-TKIs and docetaxel although studied in a certain time frame may not show a real-time trend. The observation of a decrease in deaths due to renal failure and an increase in deaths due to ILD would therefore be interpreted with great caution. Finally, the definition of 'treatment-related' deaths is somewhat vague, although we attempted to contact the principal authors of reports of each trial to clarify the results. Thus, our results should be interpreted cautiously.
In conclusion, the TRD of a patient receiving treatment of advanced NSCLC is extremely disappointing, considering the palliative aim of systemic treatment and its limited survival benefit. According to our analysis, the overall TRD rate in 
